title: Multicenter trial of naloxone in Alzheimer's disease.
abstract: In a double-blind, placebo-controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1-mg or 10-mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.
authors.affiliation: Department of Neurology, University of Southern California School of Medicine, Los Angeles 90033.
authors.forename: V W
authors.initials: VW
authors.lastname: Henderson
authors.forename: E
authors.initials: E
authors.lastname: Roberts
authors.forename: C
authors.initials: C
authors.lastname: Wimer
authors.forename: E L
authors.initials: EL
authors.lastname: Bardolph
authors.forename: H C
authors.initials: HC
authors.lastname: Chui
authors.forename: A R
authors.initials: AR
authors.lastname: Damasio
authors.forename: P J
authors.initials: PJ
authors.lastname: Eslinger
authors.forename: M F
authors.initials: MF
authors.lastname: Folstein
authors.forename: L S
authors.initials: LS
authors.lastname: Schneider
authors.forename: E L
authors.initials: EL
authors.lastname: Teng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D009483:Neuropsychological Tests
chemical_list: D009270:Naloxone